Form 10-Q Epizyme, Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
RBC Affirms Epizyme (EPZM) at 'Outperform' as Ttazemetostat Enrollment Continues
November 9, 2015 12:43 PM ESTRBC Captial affirms Epizyme (Nasdaq: EPZM) at Outperform with a price target of $39 following Q3 results and update issued earlier.
Analyst Simos Simeonidis noted the following:
Enrollment continues in 150-patient Phase II study in NHL in Europe: On their 3Q15 earnings call this morning, management stated that plans remain on track for tazemetostat's Phase II programs. Patients are currently being enrolled in the 5-arm,... More
